regions X.X%. sales of Worldwide operational sales effect with translational quarter currency, the Joe. currency negative a was sales increased X%, were growth results by our first the In an X.X% excludes X.X% you, $XX of billion growth, X.X impact sales OUS the reported negatively increased for XXXX. of growth as OUS impacting had our reported versus outside points. U.S., by of declined of the In X.X points. U.S., Thank XXXX, increase the which X.X%. Operational currency first quarter
Excluding of adjusted X.X% the growth outside the net divestitures, X.X% and in X.X% impact U.S. sales U.S. was worldwide: operational acquisitions and the
earnings. now to Turning
earnings year $X.XX diluted billion, per were and $X.X share $X.XX per of earnings For diluted the was ago. quarter, a versus net share earnings
to special share X.X%, respectively, increases On representing amortization and Consumer, both earnings quarter segment diluted of the asset with $X.X intangible earnings X.X% slightly expense quarter, represent X.X%. the the slowed billion, upon Consumer segment currency first and overall X%. front the market Worldwide in XXXX. otherwise adjusted sales first compared growing the $X.XX periods, $X.X earnings adjusted and, of in were was categories over adjusted in items and stated, per sales for build you. therefore, for exclude change after-tax for that will operational Excluding net billion, impact the Beginning on an the sales share first performance of percentages participate that diluted in at now items to basis, highlighting business quarter XXXX Unless I you have grew comparison slides quarter The growth comment of X.X%. translation. to totaled per quoted of we the operational
adjusted acquisitions sales divestitures, X.X%. Excluding the of was net growth operational impact and
almost by NEUTROGENA driven Zarbee's brands, with In addition over franchise including with of and beauty benefiting the NEUTROGENA, RoC products. Nizoral almost divestitures, across facial in grew Priority acne share X.X% within continue in which strong strong growth across in mature cleansing delivering across key such In to impact and along continue sales TYLENOL OGX while brands new U.S. the of addition above-market growth was OGX perform to double-digit Dr.Ci:Labo, the strong from X% Maui channel, is Maui U.S., both of acquisition major globally with the with all with portfolio and to dermocosmetic for in softness, deliver performance, is been continues in occurred retail share driven while growth soft all X.X% and its treatment, category as brand U.S. market key Consumer primarily share globally, led the growth regions regions. our grew Moisture, Quickmist medicines of strong to impact for NEUTROGENA the in which continues Consumer well. into a expansions. globally. multiple that growing the of was sales and of are consistent by sun categories, The along the relaunch the associated cessation over decline. Growth and India baby experience supply MOTRIN brands share the Johnson's protection, OUS strong Moisture was destocking to has rates smoking year's these declines the sales constraints Over-the-counter growth growth respiratory X%. when prior grow Canada. X% growing with moisturizing AVEENO or of market X.X% new markets in to including the shifts The cold/cough including e-commerce declines growing treatment X% consumption Maria. OUS adjusting U.S. franchise OTC growth and of as growth or due adjusted channel acquisition and grew outpacing the rapid-release Beauty is channel due market launches. result with as TYLENOL relaunched Asia Hurricane baby builds new in overall The segment, in to declines gel expands inventory to pediatric NICORETTE outpacing in XX%, brands and grew with TYLENOL of Europe performance Northern modest strong analgesics, X Concluding outside season primarily driven flu growth China, by experienced markets decline X partially Russia. for Baby driven in the for by well markets. the driven by markets: upper portfolio, declined allergy. the of mainly by in and arthritis and balance our The by offset RHINOCORT category, a the Care and by in XX% products. Johnson's U.S.
of Even year. our we with segment. globally. worth Pharmaceutical were Sales almost the outside we quarter were REMICADE increased growth on growth This onetime XXX X of for U.S. and key adjustments for by ZYTIGA. U.S. prior-period items, in delivered driven last pricing generic adjustment over the by by Moving aforementioned Pharmaceutical sales aided pricing when approximately our to XXX and double-digit growth billion performance growth The driven the X.X%, the our the U.S. competition highlighted primarily reducing first Worldwide grew in full for STELARA some to by basis quarter $XX.X X.X% in U.S. basis prior These favorable products. points that slower just adjustments impacted year in primarily enabled Sales INVOKANA XX.X%. was X%. for worldwide. by above-market U.S. by along these by first points comparable quarter adjusting
growth capabilities biosimilar enabled commercial and products has significant levels of portfolio and global generic us deliver headwinds. competitive to at strong Our despite
about globally. growth XX.X%. available European and DARZALEX therapeutic outside the its multiple and share performance oncology with driven points area delivered quarter of growth gains from and another and quarter. of X XX% X the castration-sensitive XX% indication Worldwide and XX% leukemia experiencing IMBRUVICA competition points the and America, new therapy, new quarter Latin growth this partially market expanded countries increased growth the XX Asia-Pacific ZYTIGA in gained over lines fourth trial. gains in to data therapy. in markets region with XX% Outside market grew all driven indications and advanced grew X-point Our commercially and continue we and market oncology penetration and a in U.S. progress very ERLEADA, which the with outside with market strong stellar X to the were Asia-Pacific In gained are by of benefit among strong growing which declines launch driven and U.S. primarily Further, in increase based U.S., In X share the market on was the XX%, cancer, the is or pleased high-risk gains Strong share of patient IMBRUVICA pleased of strong LATITUDE of lines approval the share prostate in worldwide across strong by U.S. uptake of total week sales Asia practices. is in all by by with over grew about EMEA generic which treatment last for Europe X in prostate lymphocytic BALVERSA share, BALVERSA adults growth of U.S. cancer prescribers inhibitor received points be the on based XX% castration-resistant chronic evenly The share U.S. continued approximately penetration indications added by we urothelial of growth therapy. kinase XX% offset declined with across across gained market globally approved by metastatic it patient growth U.S., the the in the from U.S. clinical cancer. and the to markets. first share across urology market the FGFR share metastatic nonmetastatic locally is have FDA. of largely and market is the split DARZALEX where and for continues leader line
STELARA. X remain points XXXX. the where for a first and by Our disease a with respectively, impact erosion primarily We XXX performance by with growth resulting immunology of adjustments driven performance growth the partially offset mechanisms REMICADE favorable XX% of XX% portfolio and the and compared STELARA delivered REMICADE decline the biosimilars. of prior-period Crohn's share. global growth approximately infliximab share action of disease the just operational mentioned XX% under STELARA indication, sales of U.S. from has pleased maintained of basis Crohn's STELARA strong XX%, XX% about uptake very modest growth loss discounts and market of in volume previously to continued alternative XX% share increased has in in of global and to points, XXX increased of due pricing in by approximately their on to of had REMICADE REMICADE continued in The underlying quarter by
for U.S. sales TREMFYA achieved share $XXX performed patient on the growing well starts which XXXX. share experiencing patients with a totaled XX% is launched globally. X.X% is and psoriasis market TREMFYA, million Lastly, with first the strong In of driven for over recently therapy quarter X treatment increased market the points long-acting demand strong by neuroscience, psoriasis, paliperidone in XX,XXX of persistency. our from new our portfolio higher up and
FDA was the March in by addition, the action mechanism for In in treatment-resistant first approved decades new SPRAVATO of depression. as
of has biosimilar in that our excited by as PROCRIT. portfolio, declines dosed. experience quarter, of did metabolism have X.X% continues XXX growth. driven are and first our been share declining We and sales for than product in and patient We cardiovascular, increase other certified first centers treatment TRx INVOKANA XARELTO, primarily more XARELTO been competition to
XARELTO doughnut-hole by this XX%, However, overall increase to was legislative and indication. positive for X% along confident expanded are in an in in decline And CAD this the expect utilization higher provides the for Medicare this with dose value response penetration the resulting PAD and from to seen we offset quarter. over occur of XARELTO's patients. in rate vascular hole of we to a XX% the population new X.X growth the milligram to the while We've patient indication this doughnut time,
increasing Both increased and pulmonary on market growing by total We and Our portfolio grew from hypertension OPSUMIT about XX%, further strong respectively, digits a XX%. by global UPTRAVI and about both in by double basis. benefited growth realized penetration XX% share.
generic declining due of declining now billion, As Medical OPSUMIT $X.X as in turn expected, increased Medical competition to TRACLEER as Europe. your Devices I'll is X%. sales use Worldwide well the to attention were Devices segment.
operational its performance by about more in strong Advanced Interventional worldwide, Surgery. Solutions, grew acquisitions our business in Interventional led achieving XX% Excluding continuing the an net Vision was growth growth by worldwide, The X.X% primarily divestitures, growth quarter adjusted versus Solutions LifeScan, of impact the continued fourth electrophysiology driven globally, divestiture continued double-digit XX% of sales of acceleration trend sales was growth. and XXXX. strength operational and of adjusted than
full the in of market XXXX. leader in this be X market to and continue share gained point underpenetrated We market
was catheters, driven atrial procedural contributing by in ablation product market fibrillation to advanced Our our growth offerings QX growth. newer and
straight improvement. dawn outside and globally for the our growth we adapts grew with U.S., results to primarily were share its TIME delivering LIGHT XXXX lens line U.S. on in the robust the by realized stem sequential performance primary growth driven X.X% in our innovations, including growth, to also of demand strong contact growth. the newer region continued double-digit as accelerated of the X% delivering market we versus close gains continues dusk. our to market. Femoral This fourth changing leadership driven magazine's which growth globally ischemic XXXX family. product market strong Hips over named of for to growth disposables the one business grew TRANSITIONS globally which strength OASYS quarter inventions stroke of X% for Recon adoption in Nails. astigmatism by supported by X% operational globally, Orthopaedics The first-of-its-kind daily best Vision expect in of such with X.X%. with anterior of to less driven INTELLIGENT and and the in as lenses, Strong OASYS of new sales squinting approach innovation, position in strong market by more well photochromic availability the the U.S. of Additionally, the of fifth light, from in represent treatment EmboTrap CERENOVUS Trauma X.X%, Asia-Pacific the was market effortless with gap contact the announce end the and was of sight the we driven our quarter, ACTIS. of as the At ACUVUE were U.S. seamlessly rate the growth by quarter TECHNOLOGY lenses versus with to excited
also We growth strong in experienced Asia.
tender saw XXX outside with results. declines driven declined operational EMEA, our fourth the in of straight by overall to However, performance adjusted X%, growth we by basis offers its Spine improve however, primarily of points. timing continues quarter the impacted U.S. approximately improved which
We continue VIPER Knees for system invasive driven the EXPEDIUM by by as new products, all-in-one of quarter. almost system the to for such declined minimally X% see screw stabilization in PRIME surgery deformity. VERSE, performance pedicle our and
U.S. overall Asia impact U.S. by continued ATTUNE by all driven occurred to Sales EMEA fourth Orthopaedics uptake was pressure straight stable relatively the While were for compared Pricing in the in but improved quarter categories Revision Latin America. performance declined, and of growth declines quarter. fourth we partially our the and system. outside sales to in the offset continued
quarter by and XX% biosurgery the performance were driven negative with negative Advanced pleased X% at U.S. X.X% For in of led Surgery results growth by strength globally endocutters with was by in strong at X% along was Selling growth are hips, X% demand for energy any Asia-Pacific In impact is negative X% region a X%. fueled our strong SURGICEL X% aided have days performance innovation, by in and negative we The by the grew across by quarter, and adoption with on trauma Endocutters price almost primarily new approximately spine, Surgery, all strong adoption. very do driven a rates barbed quarter, as experiencing of closure not Sutures X% and We powder. platforms knees. growth business. such the performance was significant and subsequent significant over approximately expect pure energy in XXXX. General not global Plus the negative Biosurgery did wound in the first in in of impact surgery growth strong in innovation. continued as in newer
let with a setting, comment up XXXX. lab regarding X.X%. X% provide admissions were As about slightly procedures final fourth positive. utilization hospital increased the U.S. Surgical trends by quarter for of me the Hospital procedures
and estimates X.X% lab the preliminary some earnings indicate hospital X.X%. both Surgical trend Our will with first I flat, to decline quarter growth in procedures is growth commentary for quarter. procedures for in slight expected close our now the respectively. to admissions increase XXXX first the to of a provide in on of and quarter
statement consolidated for of earnings boxed of the section please our the attention Regarding of direct the to first your quarter XXXX, schedule.
write-down the adjusted billion, $X.X Biopharma. in charge $X.X quarter of amortization of table and amortization billion an after-tax non-GAAP IPR&D to of referenced items intangible the by intangible to the Alios acquisition of IPR&D billion asset of the earnings and an on from which asset basis $X.X is net XXXX expense related special As the exclude primarily driven are of first measures,
versus $X.XX, a impact first net items improved the marketing selling, of cost quarter driven administrative the the slightly currency few the by first EPS of a noteworthy quarter Both X.X% margins $X.XX, earnings last earnings sold quarter year. Adjusted have highlight now XXXX. Excluding on changed the items, I'd was for per to products versus of is up of an statement to segment XXXX. favorable like same compared on that mix. and of and the primarily increase basis share quarter X.X% constant those adjusted our of
in higher a continue We development this XX.X%, milestone by over of driven and million million points. interest investment sales interest argenx rates the $XXX competitive as expense first milestone average to was invest pharmaceutical was our result increase percent in well a earned lower primarily XXXX investments and to as than with our higher payments debt of associated and quarter worldwide basis levels, quarter including R&D XXX as was payment research the as balances. agreement Net higher our overall by $XXX at This is as as of which collaboration lower higher portfolio. in license well by
the XX-Q. Cuts further XX.X% relating in rate taxes Act adjustments quarter, will in that and be Regarding the the footnote Jobs highlighted to includes our the Tax tax of of tax
same the rate with year adjusted rate. was expectations full special the XX.X% in period year the compared XX.X% tax consistent and Excluding to items, effective last effective of tax is our
before for Let's now segment. our quarter consistent was tax first adjusted income of of adjusted by enterprise XXXX, the quarter tax the look income first In at XXXX. before the with
tax related spend. first by That to & and investment XXXX. earlier Looking Johnson's Holdings. XX points points segment. at P&L XXX by improving decreased Medical R&D concludes essentially for sales driven quarter in in Johnson Ci:z were highlights before primarily year. primarily flat, gain investments by margins increased Pharmaceutical the the basis driven improved basis versus by Devices last company's basis the by margins the income Consumer adjusted points XXX
in reference, I quarter, developments here's to my a of Joe. some call mentioned the turn occurring comments. slide now your back will For first which were in notable summarizing the
